Dzhintropin is a recombinant somatotropic hormonal agent.
Release form and composition
Dzhintropin lyophilisate is produced to prepare a solution for sc administration with the content of somatropin active substance in dosages of 4 IU and 10 IU. Auxiliary substances of the drug are glycine, mannitol, sodium chloride, sodium dihydrogen phosphate.
Indications for use
According to the instructions, Dzhintropin is indicated for use in the following cases:
- Growth retardation in children as a result of insufficient synthesis of somatropin in the body (growth hormone), chronic renal failure (renal function is reduced by 50% or more) in the prepubertal period, gonadal dysgenesis (Shereshevsky-Turner syndrome);
- Lack of somatropin in adults of congenital or acquired nature (as a replacement therapy).
According to the instructions, Dzhintropin should not be used when:
- Malignant tumors;
- Active intracranial neoplasms;
- Pregnancy and breastfeeding;
- Depressed conditions, including those arising after operations on the abdominal cavity, heart, or as a result of acute respiratory failure;
- Hypersensitivity to the active or auxiliary components of the drug.
With caution Dzhintropin prescribed for hypothyroidism, increased intracranial pressure, diabetes.
Dosing and Administration
Dzhintropin apply p / to. The drug is administered slowly once a day (preferably before bedtime). It is recommended to periodically change the injection site in order to prevent the development of lipoatrophy.
Before use, the contents of the vial must be dissolved in 1 ml of the attached solvent. To do this, the solvent is collected in a syringe and injected into the vial with the drug through the cork, gently rocking the vial until the contents dissolve completely (no shaking is allowed). The finished solution can be stored at a temperature of 2-8 ° C for no longer than two weeks.
The dosage of the drug is selected individually depending on the patient's age, growth hormone deficiency and the effectiveness of the therapy.
With insufficient synthesis of growth hormone in children, the recommended dose of dzhintropina is 0.07-0.1 IU per kg of body weight per day. It is recommended to begin treatment as early as possible and continue until puberty or until the bone growth zones are closed. Upon reaching the desired result of treatment, it is possible to stop the use of Dzhintropina.
When gonadal dysgenesis and chronic renal failure in children causing growth retardation, Dzhintropin is prescribed at a dose of 0.14 IU per kg of body weight per day.
With a lack of growth hormone in adults, treatment with Dzhintropin begins with a dose of 0.45-0.9 IU per kg of body weight per day, followed by an increase depending on the effectiveness of therapy. The maintenance dose, as a rule, does not exceed 3 IU per day.
The use of Dzhintropina can cause the following adverse reactions from various systems of vital activity of an organism:
- Increased intracranial pressure, manifested by nausea and vomiting, severe headache, visual impairment;
- Fluid retention with the occurrence of peripheral edema;
- Leukemoid reactions;
- Tunnel syndrome;
- Myalgia, arthralgia;
- Epiphysiolysis of the femoral head;
- Allergies in the form of itching, skin rash;
- Local reactions in the form of swelling, hyperemia, goiter, pain, lipoatrophy at the injection site.
In rare cases, the patient may form antibodies to the drug, which causes a decrease in its effectiveness.
During therapy with Dzhintropin, it may be necessary to adjust the doses of hypoglycemic agents in patients with diabetes. Also, manifestation of hypothyroidism, previously proceeding covertly, is not excluded. If the patient is taking thyroxin, symptoms of hyperthyroidism may appear during treatment with Jintropin.
For the entire period of treatment with Dzhintropin, patients should monitor the condition of the fundus, especially if there are signs of increased intracranial pressure. If optic nerve edema occurs, use of Dzhintropin should be stopped.
If during the treatment with Dzhintropin the patient begins to limp unexpectedly, it is recommended to undergo a thorough examination.
In the case of prolonged use of the drug in excessive doses, the development of an overdose is possible, manifested first by hypoglycemia, and later by hyperglycemia. With a prolonged overdose of Dzhintropin, symptoms may occur when an excessive synthesis of growth hormone in the body occurs - gigantism, acromegaly, hypothyroidism, a decrease in the serum level of cortisol.
In the presence of the above symptoms, therapy with Dzhintropin should be stopped and symptomatic treatment should be carried out.
The stimulating effect of somatropin on growth processes reduces the simultaneous intake of glucocorticosteroids. Also, the effectiveness of the drug can affect the concomitant treatment with hormones, for example, anabolic steroids, gonadotropin, thyroid hormones, estrogen.
During pregnancy, the use of Dzhintropina absolutely contraindicated. If there is a need for drug therapy during lactation, it is recommended to stop breastfeeding for the period of treatment.
Structural analogues Dzhintropina and drugs that have similar pharmacological effects are the following drugs:
- Norditropin 12;
Terms and conditions of storage
According to the instructions, Dzhintropin should be stored at 2-8 ° C, in a place protected from moisture and direct sunlight, out of reach of children. The shelf life of the drug is 2 years. The drug is forbidden to freeze and use after the expiration date.